Presentation of multiple myeloma mimicking bone metastasis from colon adenocarcinoma: A case report and literature review

Zhang,Haicheng; Lv,Jurong; Lv,Chaoliang; Zhang,Hongmei

doi:10.3892/mco.2015.650

Presentation of multiple myeloma mimicking bone metastasis from colon adenocarcinoma: A case report and literature review

Authors:
- Haicheng Zhang
- Jurong Lv
- Chaoliang Lv
- Hongmei Zhang
View Affiliations

Affiliations: Department of Surgery, Jinxiang People's Hospital, Jining, Shandong 272200, P.R. China, Department of Spine Surgery, Jining No. 1 People's Hospital, Jining, Shandong 272011, P.R. China
Published online on: October 2, 2015 https://doi.org/10.3892/mco.2015.650
Pages: 31-34
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We herein present the case report of a 83‑year‑old female patient who had undergone right colon resection for adenocarcinoma 2 years earlier, and developed osteolytic lesions of the right femur 6 months ago. A roentgenogram of the right thigh, technetium‑99m phosphate bone scintigraphy and combined 18f‑fluoro‑2‑deoxy‑d‑glucose positron emission tomography/computed tomography imaging were performed, and the results revealed multiple osteolytic lesions in the humerus bilaterally, the right scapula and the right femur. The lesions were suspected to be colon cancer metastases. To improve the quality of life of the patient, palliative surgery was performed. However, the intraoperative biopsy of the focal lesions and immunohistochemical evaluation revealed multiple myeloma (MM). Chemotherapy was administered 2 weeks after surgery and the patient recovered uneventfully. The manifestations of MM and bone metastases are occasionally similar. Although the coexistence of the two diseases is rare, both conditions should be considered in the differential diagnosis of osteolytic lesions.

View Figures

View References

1	Kanthan R, Loewy J and Kanthan SC: Skeletal metastases in colorectal carcinomas: A Saskatchewan profile. Dis Colon Rectum. 42:1592–1597. 1999. View Article : Google Scholar : PubMed/NCBI
2	Besbeas S and Stearns MW Jr: Osseous metastases from carcinomas of the colon and rectum. Dis Colon Rectum. 21:266–268. 1978. View Article : Google Scholar : PubMed/NCBI
3	Chang CY, Peng YJ, Shen DH, Huang WS and Cherng SC: Detection of multiple myeloma by PET/CT in a patient with colon cancer. Clin Nucl Med. 33:367–370. 2008. View Article : Google Scholar : PubMed/NCBI
4	Yermiahu T, Peiser J, Benharroch D and Ovnat A: Aggressive behavior of carcinoma of the colon associated with nonsecreting plasma cell myeloma. A case report. J Clin Gastroenterol. 11:565–567. 1989. View Article : Google Scholar : PubMed/NCBI
5	Zaidi AA and Vesole DH: Multiple myeloma: An old disease with new hope for the future. CA Cancer J Clin. 51:273–285. 2001. View Article : Google Scholar : PubMed/NCBI
6	Tan D, Chng WJ, Chou T, Nawarawong W, Hwang SY, Chim CS, Chen W, Durie BG and Lee JH: Management of multiple myeloma in Asia: Resource-stratified guidelines. Lancet Oncol. 14:e571–e581. 2013. View Article : Google Scholar : PubMed/NCBI
7	Kyle RA: Multiple myeloma. An update on diagnosis and management. Acta Oncol. 29:1–8. 1990. View Article : Google Scholar : PubMed/NCBI
8	Kyle RA and Rajkumar SV: Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 23:3–9. 2009. View Article : Google Scholar : PubMed/NCBI
9	Kyle RA, Therneau TM, Rajkumar SV, Remstein ED, Offord JR, Larson DR, Plevak MF and Melton LJ III: Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood. 102:3759–3764. 2003. View Article : Google Scholar : PubMed/NCBI
10	Snozek CLH, Katzmann JA, Kyle RA, Dispenzieri A, Larson DR, Therneau TM, Melton LJ III, Kumar S, Greipp PR, Clark RJ, et al: Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: Proposed incorporation into the international staging system. Leukemia. 22:1933–1937. 2008. View Article : Google Scholar : PubMed/NCBI
11	International Myeloma Working Group: Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol. 121:749–757. 2003. View Article : Google Scholar : PubMed/NCBI
12	Jadvar H and Conti PS: Diagnostic utility of FDG PET in multiple myeloma. Skeletal Radiol. 31:690–694. 2002. View Article : Google Scholar : PubMed/NCBI
13	Schirrmeister H, Bommer M, Buck AK, Müller S, Messer P, Bunjes D, Döhner H, Bergmann L and Reske SN: Initial results in the assessment of multiple myeloma using ¹⁸F-FDG PET. Eur J Nucl Med Mol Imaging. 29:361–366. 2002. View Article : Google Scholar : PubMed/NCBI
14	Rajkumar SV: Treatment of myeloma: Cure vs. control. Mayo Clin Proc. 83:1142–1145. 2008. View Article : Google Scholar : PubMed/NCBI
15	Haessler J, Shaughnessy JD Jr, Zhan F, Crowley J, Epstein J, van Rhee F, Anaissie E, Pineda-Roman M, Zangari M, Hollmig K, et al: Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res. 13:7073–7079. 2007. View Article : Google Scholar : PubMed/NCBI
16	Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Lentzsch S, Munshi N, Niesvizky R, et al: International Myeloma Working Group: Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood. 114:1729–1735. 2009. View Article : Google Scholar : PubMed/NCBI
17	Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, Niesvizky R, Morgan G, Comenzo R, Sonneveld P, et al: IMWG: International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia. 23:1716–1730. 2009. View Article : Google Scholar : PubMed/NCBI
18	Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, et al: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 335:91–97. 1996. View Article : Google Scholar : PubMed/NCBI
19	Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT and Selby PJ: Medical Research Council Adult Leukaemia Working Party: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 348:1875–1883. 2003. View Article : Google Scholar : PubMed/NCBI
20	Blade J, Vesole DH and Gertz M: Transplantation for multiple myeloma: Who, when, how often? Blood. 102:3469–3477. 2003. View Article : Google Scholar : PubMed/NCBI
21	Kumar A, Loughran T, Alsina M, Durie BG and Djulbegovic B: Management of multiple myeloma: A systematic review and critical appraisal of published studies. Lancet Oncol. 4:293–304. 2003. View Article : Google Scholar : PubMed/NCBI
22	Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, Macro M, Pertuiset E, Dreyfus F, Mariette X, et al: High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 92:3131–3136. 1998.PubMed/NCBI
23	Facon T, Mary JY, Harousseau JL, et al: Front-line or rescue autologous bone marrow transplantation (ABMT) following a first course of high dose melphalan (HDM) in multiple myeloma (MM). Preliminary results of a prospective randomized trial (CIAM) protocol. Blood. 88(Suppl 1): 685a1996.
24	Barlogie B, Kyle R, Anderson K, et al: Comparable survival in multiple myeloma (MM) with high dose therapy (HDT) employing MEL 140 mg/m² TBI 12 Gy autotransplants vs. standard dose therapy with VBMCP and no benefit from interferon (IFN) maintenance: Results of intergroup Trial S9321. Blood. 102:42a2003.